Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 28, 2026. Pasithea Therapeutics Corp., an emerging growth company incorporated in Delaware, held a Special Meeting of Stockholders to approve significant corporate governance and capital structure amendments.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Corporate Actions
Stockholders approved two primary proposals at the Special Meeting:
- Authorized Share Increase: The Company amended its Certificate of Incorporation to increase authorized Common Stock from 100,000,000 shares to 500,000,000 shares.
- Stock Incentive Plan Expansion: The 2023 Stock Incentive Plan was amended to increase the number of shares authorized for issuance by 11,985,779 shares, bringing the total to 14,000,000 shares.
Voting Results
Out of 23,091,062 shares outstanding, 16,746,261 shares were represented at the meeting, constituting a quorum.
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| 1. Increase Authorized Shares | 16,066,757 | 647,972 | 31,532 | N/A |
| 2. Amend 2023 Incentive Plan | 8,168,126 | 4,550,855 | 5,569 | 4,021,711 |
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on financial performance, or specific risk factors beyond the standard incorporation of the full text of the Plan Amendment and Certificate of Amendment by reference.
Key Facts for Investor Verification
- Verify the impact of the 5x increase in authorized shares on potential future dilution.
- Review the full text of the Second Amendment to the 2023 Stock Incentive Plan (Exhibit 10.1) to understand vesting terms and eligibility for the additional 11.9 million shares.
- Note the significant number of broker non-votes (4,021,711) on the Incentive Plan proposal, indicating institutional holders did not vote on this discretionary matter.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.